glp-1 agonists market Receptor Agonist Size, Share & Forecast, 2026–2034 GLP-1 Analogues Market Size to

You may still be eligible for the PAP if you have Medicare Part D and have spent at least $1,000 out-of-pocket on medication purchases in the calendar year

GLP-1s are medications for type 2 diabetes and weight management that are injected (or taken orally) daily or weekly

Rossetti CL, Andrade IS, Fonte Boa LF, Neves MB, Fassarella LB, Bertasso IM, et al

After approving oral Wegovy in December 2025, the FDA has now also approved Clinical trial data shows that participants taking Foundayo achieved meaningful weight loss compared with placebo, reinforcing its potential as an effective treatment option

some payors now approve GLP-1s for obesity), though high out-of-pocket costs still limit access a Kaiser Family Foundation survey found ~55% of GLP-1 users struggle to afford their medication ( [1] )

The same study also illustrated that upregulation of GLP-1 via gene transfer was associated with enhanced learning and memory, providing evidence of the role GLP-1 has in hippocampal function [57]